Tumour sites with low prostate-specific membrane antigen (PSMA)-avidity and high fluorodeoxyglucose (FDG)-avidity represent sites of aggressive disease, which cannot be effectively targeted by radioligand therapy. The gene discussed is FOLH1; the disease is neoplasm.